Brief: Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy
13/03/2025 12:13
March 13 (Reuters) - COSCIENS Biopharma Inc CSCI.TO: COSCIENS BIOPHARMA INC. ANNOUNCES SUCCESSFUL PHASE 1 RESULTS SUPPORTING INITIATION OF PHASE 2A CLINICAL EFFICACY TRIAL WITH AVENANTHRAMIDES AS A POTENTIAL ANTI-INFLAMMATORY PRODUCT Source text: ID:nGNX2L8H8z Further company coverage: CSCI.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COSCIENS Biopharma
See all newsBrief: COSCIENS Acquires Nualtis Corp
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update